For AD, the amyloid/tau/neurodegeneration or “AT(N)” criteria, using CSF and/or PET imaging, has been instrumental in accurately detecting both the presence of Aβ and tau pathology, and to stage patients along the AD continuum.9 Here, MAPT is linked to Alzheimer disease.